Vaccinogen works on the radical simplicity route of a renewable antibody-target pairing engine called OncaVERT.

Vaccinogen Inc. is a registration-stage biotechnology company redefining how cancer is treated by shifting intervention to the moment when a cure remains biologically achievable. The company’s lead program, OncoVAX®, is an autologous, tumor-derived immunotherapy developed to prevent recurrence in Stage II and beyond in colon cancer. Unlike conventional therapies that attempt to eradicate metastatic disease after it has spread, OncoVAX® harnesses the patient’s own tumor to train the immune system immediately after surgical excision, when microscopic disease is still vulnerable. The therapy combines irradiated autologous tumor cells with a brief immune-priming step that recruits a broad array of effector and antigen-presenting cells. This transforms the injection site into a biological training ground where the immune system learns to identify and eliminate residual malignant cells before they seed distant organs. This biologically timed intervention addresses a fundamental limitation of oncology: the heterogeneity of cancer. By leveraging the full antigenic signature of each patient’s tumor, OncoVAX® generates a personalized, polyclonal immune response that neutralizes micrometastatic disease at its inception. In long-term follow-up from a Phase IIIa study, this approach has demonstrated durable protection extending beyond fifteen years, an outcome rarely observed in solid-tumor immunotherapy. Vaccinogen aims to complete its FDA Special Protocol Assessment–aligned Phase IIIb registrational trial, advance to Biologics License Application submission, and transition to commercial readiness. OncoVAX® stands as a model for precision immunology: a treatment that transforms cancer management into true cancer prevention.

Founded 2007